Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium
Byung Ha Chung, R. Valdagni, Mieke Van Hemelrijck(Ghent University Hospital), Prokar Dasgupta(King's College London), Phillip D. Stricker(Prostate Cancer Foundation of Australia), Caroline M. Moore(University College London Hospitals NHS Foundation Trust), Christopher J. Logothetis(The University of Texas MD Anderson Cancer Center), Bruce J. Trock(Johns Hopkins University), Christopher P. Filson(Emory University), Behfar Ehdaie(NewYork–Presbyterian Hospital), Anders Bjartell(Lund University), J. Rubio‐Briones, Jonas Hugosson(Sahlgrenska University Hospital), Daan Nieboer(Erasmus MC), Vincent J. Gnanapragasam(Addenbrooke's Hospital), Todd M. Morgan(University of Michigan), Jozien Helleman(Erasmus MC), Lee Lui Shiong(Singapore General Hospital), Andrew Hayen(University of Technology Sydney), Antti Rannikko(Royal Free London NHS Foundation Trust), Monique J. Roobol(Erasmus MC), Brian T. Denton(University of Michigan), Mark Frydenberg(Monash University), Lukas Hefermehl, Tom Pickles, Ivo G. Schoots(Erasmus MC), Laurence Klotz(University of Toronto), Antoinette S. Perry, Axel Semjonow, Weiyu Li(University of Michigan), Masoom A. Haider(Princess Margaret Cancer Centre), Chris H. Bangma(Erasmus MC), Eric Hyndman
Cited by 27
Related Papers
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2012|1.4k